UI Hospitals and Clinics
A phase II, multicenter, single-arm study of oral LDK378 in crizotinib naive adult patients with ALK-activated non-small cell lung cancer
Participants in this research study have a particular type of lung cancer called ‘ALK positive’ non-small lung cancer and have already performed the pre-screening part of the study, which was the test for ALK status. Participants in this study will be asked to take LDK378 capsules once a day. LDK378 is a medicine which has not been approved by the US Food and Drug Administration for the treatment of people with this medical condition. Approximately 105 patients at about 25 centers from around the world will participate in this study.
Pam Zehr, 319-353-8914
We welcome your feedback! Please help us improve your experience on our website by completing a brief survey.